Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histone Deacetylase Inhibitors Reverse SS18-SSX–Mediated Polycomb Silencing of the Tumor Suppressor <i>Early Growth Response 1</i> in Synovial Sarcoma

1 Jun 2008

Abstract excerpt

Synovial sarcoma is a soft tissue malignancy characterized by the fusion of SS18 to either SSX1, SSX2, or SSX4 genes. SS18 and SSX are transcriptional cofactors involved in activation and repression of gene transcription, respectively. SS18 interacts with SWI/SNF, whereas SSX associates with the polycomb chromatin remodeling complex. Thus, fusion of these two proteins brings together two opposing effects on gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18519690
DOI: 10.1158/0008-5472.can-08-0092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histone Deacetylase Inhibitors Reverse SS18-SSX–Mediated Polycomb Silencing of the Tumor Suppressor <i>Early Growth Response 1</i> in Synovial SarcomaPMID 18519690Read ↗

The Synovial Sarcoma–Associated SS18-SSX2 Fusion Protein Induces Epigenetic Gene (De)RegulationSemantic proximity Read ↗

Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for TherapySemantic proximity Read ↗

The (Epi)genetics of human synovial sarcomaSemantic proximity Read ↗

Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stabilitySemantic proximity Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatmentSemantic proximity Read ↗

SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activitySemantic proximity Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

DNA demethylating agents suppress preclinical models of synovial sarcomaSemantic proximity Read ↗

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial SarcomaSemantic proximity Read ↗

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcomaSemantic proximity Read ↗

ATR Is a Therapeutic Target in Synovial SarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.